FDA label 3b6ecafa-deef-41cd-932b-4064418a3a82

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
4e4bc43f-892a-4ca4-ad43-5383c276c61e
SPL ID
3b6ecafa-deef-41cd-932b-4064418a3a82
Version
17
Effective date
2020-07-10
Source export date
2026-11-13
Source partition
7
Source file
https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:35:17

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS • Hypersensitivity reactions, including anaphylaxis, are possible. Should symptoms occur, discontinue treatment with Helixate FS and administer appropriate treatment ( 5.1 ). • Development of activity-neutralizing antibodies can occur in patients receiving factor VIII-containing products, including Helixate FS. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration ( 5.2 ). • When clotting is normalized by treatment with factor VIII, development of cardiovascular risk factors may be the same as the risk for non-hemophilic patients ( 5.3 ). • Monitor plasma factor VIII levels during infusions when indicated ( 5.4 ). 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis have been reported with Helixate FS. Reported symptoms included facial swelling, flushing, hives, decrease in blood pressure, nausea, rash, restlessness, shortness of breath, tachycardia, tightness of the chest, tingling, urticaria, and vomiting. Helixate FS contains trace amounts of mouse immunoglobulin G (MuIgG) and hamster (BHK) proteins [ see Description (11) ]. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins. Discontinue Helixate FS if symptoms occur and seek immediate emergency treatment. 5.2 Neutralizing Antibodies Neutralizing antibodies (inhibitors) have been reported following administration of Helixate FS, predominantly in previously untreated patients (PUPs) [ see Adverse Reactions (6) ]. Carefully monitor patients for the development of factor VIII inhibitors, using appropriate clinical observations and laboratory tests. 6 If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration [ see Warnings and Precautions (5.4) ]. 5.3 Cardiovascular Risk Factors Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with factor VIII. 5.4 Monitoring Laboratory Tests • Monitor plasma factor VIII activity levels by the one-stage clotting assay to confirm the adequate factor VIII levels have been achieved and maintained, when clinically indicated [ see Dosage and Administration (2) ]. • Monitor for development of factor VIII inhibitors. Perform assay to determine if factor VIII inhibitor is present. If expected factor VIII activity plasma levels are not attained or if bleeding is not controlled with the expected dose of Helixate FS, use Bethesda Units (BU) to titer inhibitors. • If the inhibitor is less than 10 BU per mL, the administration of additional Helixate FS concentrate may neutralize the inhibitor and may permit an appropriate hemostatic response. • If inhibitor titers are above 10 BU per mL, adequate hemostasis may not be achieved. The inhibitor titer may rise following Helixate FS infusion as a result of an anamnestic response to factor VIII. The on-demand treatment and control of bleeding in such patients requires the use of alternative therapeutic approaches and agents.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 4 matching rows.

adverse reactions

6 ADVERSE REACTIONS Serious adverse reactions seen with Helixate FS are systemic hypersensitivity reactions, including bronchospastic reactions and/or hypotension and anaphylaxis, and the development of high-titer inhibitors necessitating alternative treatments to factor VIII. The most common adverse reactions (≥ 4%) observed in clinical trials were inhibitor formation in previously untreated patients (PUPs) and minimally treated patients (MTPs), skin-related hypersensitivity reactions (e.g., rash, pruritus), infusion site reactions (e.g., inflammation, pain), and central venous access device (CVAD) associated infections. The most common adverse reactions (≥4%) in clinical trials are inhibitor formation (neutralizing antibodies) in previously untreated and minimally treated patients (PUPs and MTPs), skin-associated hypersensitivity reactions (e.g., rash, pruritus, urticaria), infusion site reactions (e.g., inflammation, pain), and central venous access device (CVAD) associated infections. To report SUSPECTED ADVERSE REACTIONS, contact CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. Previously Treated Patients (PTPs) During the open-label clinical studies conducted in 73 PTPs, there were 24 adverse reactions reported in the course of 24,936 infusions. Adverse reactions reported by ≥ 4% of the patients are listed in Table 3 below. Table 3 Adverse Reactions (AR) in Previously Treated Patients with Frequency of ≥ 4% (Age Range 12–59 years) MedDRA Primary SOC Preferred Term N = 73 AR (%) SOC = System Organ Class Skin and Subcutaneous Tissue Disorders Rash, pruritus 6 (8.2%) General Disorders and Administration Site Conditions Infusion site reactions 3 (4.1%) Previously Untreated Patients (PUPs) and Minimally Treated Patients (MTPs) In clinical studies with pediatric PUPs and MTPs, there were 29 adverse reactions reported in the course of 9,389 infusions. Adverse reactions reported by ≥ 4% of the patients are listed in Table 4 below. Table 4 Adverse Reactions (AR) in Previously Untreated Patients and Minimally Treated Patients with Frequency of ≥ 4% (Age Range 2–27 months) MedDRA Primary SOC Preferred Term N = 61 AR (%) SOC = System Organ Class Skin and Subcutaneous Tissue Disorders Rash, pruritus, urticaria 10 (16%) Blood and Lymphatic System Disorders Factor VIII inhibition (neutralizing antibodies) 9 (15%) Denominator for de novo inhibitors is N = 60, since one patient had a pre-existing inhibitor. General Disorders and Administration Site Conditions Infusion site reactions 4 (7%) Minimally Treated Patients (MTPs) in the Joint Outcome Study In the Joint Outcome Study with pediatric MTPs treated with routine prophylaxis or episodic enhanced treatment for 5.5 years, 46 of the 65 randomized patients experienced adverse events over the study duration. Table 5 Adverse Reactions in Minimally Treated Patients in the Joint Outcome Study (Age Range 0–6 years) MedDRA Primary SOC Preferred Term Prophylaxis Arm N = 32 AR (%) Enhanced Episodic Arm N = 33 AR (%) SOC = System Organ Class Surgical and Medical Procedures Central venous catheterization, Catheter removal 19 (59%) 18 (55%) Three patients from the enhanced episodic arm had catheter removal. Infections and Infestations Central line infection 6 (19%) 6 (18%) General Disorders and Administration Site Conditions Pyrexia 1 (3%) 4 (12%) Immunogenicity In clinical studies with 73 PTPs (defined as having more than 100 exposure days), one patient had a pre-existing inhibitor. In the other 72 patients, followed over 4 years, no de novo inhibitors were observed. In clinical studies with pediatric PUPs and MTPs, inhibitor development was observed in 9 out of 60 patients (15%), 6 were high titer 1 (> 5 BU) and 3 were low-titer inhibitors. Inhibitors were detected at a median number of 7 exposure days (range 2 to 16 exposure days). In the Joint Outcome Study with Helixate FS, 5 de novo inhibitor development was observed in 8 of 64 patients with negative baseline values (12.5%), 2 patients developed high titer 1 (> 5 BU) and were withdrawn from the study. Six patients developed low-titer inhibitors. Inhibitors were detected at a median number of 44 exposure days (range 5 to 151 exposure days). Inhibitor data in PUPs have been collected in several postmarketing registries [ see Postmarketing Experience (6.2) ]. The detection of antibody formation is dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Helixate FS with the incidence of antibodies to other products may be misleading. 6.2 Postmarketing Experience Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reaction has been identified during post approval use of Helixate FS: Sensory System – Dysgeusia Immunogenicity – Postmarketing Registries Data from the Research of Determinants of Inhibitor Development (RODIN) study 7 , French National Registry (FranceCoag) 8 and United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) 9 registry reported an inhibitor development rate in PUPs for Hexliate FS of 38%, 50% and 35%, respectively, which is comparable to previously-reported inhibitor rates 10 for FVIII products. These registry studies show a trend towards an increased risk of inhibitor development in PUPs, as compared to the reference rFVIII product. A survey of Canadian hemophilia centers 11 (2005 to 2012) and available data from the European Haemophilia Safety Surveillance (EUHASS) 12 registry from 2009 to 2013, reported an inhibitor development rate in PUPs for Helixate FS of 42% and 31%, respectively, with no statistically significant differences observed across FVIII products.

adverse reactions table

<table ID="_RefID0ENVAG" width="95%"><caption>Table 3 Adverse Reactions (AR) in Previously Treated Patients with Frequency of &#x2265; 4% (Age Range 12&#x2013;59 years)</caption><col width="50%"/><col width="25%"/><col width="25%"/><thead><tr><th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="top"><content styleCode="bold">MedDRA Primary SOC</content></th><th align="left" styleCode="Rrule Botrule Toprule " valign="top"><content styleCode="bold">Preferred Term</content></th><th align="left" styleCode="Rrule Botrule Toprule " valign="top"><content styleCode="bold">N = 73 AR (%)</content></th></tr></thead><tfoot><tr><td align="left" colspan="3" styleCode="Botrule" valign="top"><content styleCode="bold">SOC = System Organ Class</content></td></tr></tfoot><tbody><tr><td styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>Skin and Subcutaneous Tissue Disorders</paragraph></td><td styleCode="Rrule Toprule Botrule " valign="top"><paragraph>Rash, pruritus</paragraph></td><td styleCode="Rrule Toprule Botrule " valign="top"><paragraph>6 (8.2%)</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>General Disorders and Administration Site Conditions</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Infusion site reactions</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>3 (4.1%)</paragraph></td></tr></tbody></table>

adverse reactions table

<table ID="_RefID0EMXAG" width="95%"><caption>Table 4 Adverse Reactions (AR) in Previously Untreated Patients and Minimally Treated Patients with Frequency of &#x2265; 4% (Age Range 2&#x2013;27 months)</caption><col width="40%"/><col width="40%"/><col width="20%"/><thead><tr><th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="top"><content styleCode="bold">MedDRA Primary SOC</content></th><th align="left" styleCode="Rrule Botrule Toprule " valign="top"><content styleCode="bold">Preferred Term</content></th><th align="left" styleCode="Rrule Botrule Toprule " valign="top"><content styleCode="bold">N = 61 AR (%)</content></th></tr></thead><tfoot><tr><td align="left" colspan="3" styleCode="Botrule" valign="top"><content styleCode="bold">SOC = System Organ Class</content></td></tr></tfoot><tbody><tr><td styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>Skin and Subcutaneous Tissue Disorders</paragraph></td><td styleCode="Rrule Toprule Botrule " valign="bottom"><paragraph>Rash, pruritus, urticaria</paragraph></td><td styleCode="Rrule Toprule Botrule " valign="bottom"><paragraph>10 (16%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>Blood and Lymphatic System Disorders</paragraph></td><td styleCode="Rrule Botrule " valign="bottom"><paragraph>Factor VIII inhibition (neutralizing antibodies)</paragraph></td><td styleCode="Rrule Botrule " valign="bottom"><paragraph>9 (15%)<footnote ID="_RefID0ECZAG">Denominator for <content styleCode="italics">de novo</content> inhibitors is N = 60, since one patient had a pre-existing inhibitor.</footnote></paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="middle"><paragraph>General Disorders and Administration Site Conditions</paragraph></td><td styleCode="Rrule Botrule " valign="bottom"><paragraph>Infusion site reactions</paragraph></td><td styleCode="Rrule Botrule " valign="bottom"><paragraph>4 (7%)</paragraph></td></tr></tbody></table>

adverse reactions table

<table ID="_RefID0EB1AG" width="95%"><caption>Table 5 Adverse Reactions in Minimally Treated Patients in the Joint Outcome Study (Age Range 0&#x2013;6 years)</caption><col width="30%"/><col width="25%"/><col width="25%"/><col width="20%"/><thead><tr><th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="top"><content styleCode="bold">MedDRA Primary SOC</content></th><th align="left" styleCode="Rrule Botrule Toprule " valign="top"><content styleCode="bold">Preferred Term</content></th><th align="left" styleCode="Rrule Botrule Toprule " valign="top"><content styleCode="bold">Prophylaxis Arm N = 32 AR (%)</content></th><th align="left" styleCode="Rrule Botrule Toprule " valign="top"><content styleCode="bold">Enhanced Episodic Arm N = 33 AR (%)</content></th></tr></thead><tfoot><tr><td align="left" colspan="4" styleCode="Botrule" valign="top"><content styleCode="bold">SOC = System Organ Class</content></td></tr></tfoot><tbody><tr><td styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph><content styleCode="bold">Surgical and Medical Procedures</content></paragraph></td><td styleCode="Rrule Toprule Botrule " valign="top"><paragraph>Central venous catheterization, Catheter removal</paragraph></td><td styleCode="Rrule Toprule Botrule " valign="top"><paragraph>19 (59%)</paragraph></td><td styleCode="Rrule Toprule Botrule " valign="top"><paragraph>18 (55%)<footnote ID="_RefID0EX2AG">Three patients from the enhanced episodic arm had catheter removal.</footnote></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">Infections and Infestations</content></paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Central line infection</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>6 (19%)</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>6 (18%)</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph><content styleCode="bold">General Disorders and Administration Site Conditions</content></paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Pyrexia</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>1 (3%)</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>4 (12%)</paragraph></td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.